1st February 2019
Last July, Oxford Cannabinoid Technologies raised $10m in equity finance. This was a significant moment in the UK’s investment scene, representing the first equity investment into a medicinal marijuana startup in nearly two decades (since GW Pharmaceuticals listed on the AIM in 2001).
Given the increasing noise about the potential of cannabis-derived drugs, and the increasingly soft stance of Home Secretary Sajid Javid, we predicted that this sector was on the tipping point of an investment “green rush”.
Our predictions have so far been borne out. Later in July Grow Biotech raised £2m in equity finance, at a £14m pre-money valuation. Under the helm of Ben Langley, an ex-Morgan Stanley trader, Grow Biotech is looking to bridge the gap between science and market in the medicinal marijuana sector. Essentially, they are looking to develop pharmaceutical IP, based on cannabis-derived compounds. Currently, they are in their R&D phase.